Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Haibo Mou"'
Publikováno v:
Photonics, Vol 11, Iss 1, p 18 (2023)
Visible light communication has the advantages of large bandwidth, high security, and no RF interference, among which LED light sources are an important light source for indoor visible light communication. The use of LED as a light source for visible
Externí odkaz:
https://doaj.org/article/054d262ec51d42918596afe9b387b733
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Immune checkpoint inhibitors (ICI) have dramatically transformed the treatment landscape for metastatic colorectal cancer (mCRC) with deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H). Envafolimab, a novel programmed dea
Externí odkaz:
https://doaj.org/article/faf7f522b2524f5d812c45de5a9dd1b8
Autor:
Xiangming Fang, Haibo Mou, Xinxin Ying, Xuehua Hou, Luo Wang, Ying Wu, Naimeng Yan, Lijie Guo, Qin Liao
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Advanced or recurrent mucinous carcinoma of the ovary minimally responds to current cytotoxic treatments and has a poor prognosis. Despite multimodal treatment with chemotherapy and surgery, most patients ultimately progress and require palliative sy
Externí odkaz:
https://doaj.org/article/d76ad878cf7e423191845909626124f1
Publikováno v:
Kidney Diseases, Pp 1-18 (2021)
Background: Cells of the immune system can inhibit tumor growth and progression; however, immune cells can also promote tumor cell growth, survival, and angiogenesis as a result of the immunosuppressive microenvironments. In the last decade, a growin
Externí odkaz:
https://doaj.org/article/dd00e2d01727451f8ec05a3a9456a953
Autor:
Haibo Mou, Lanfang Yu, Qin Liao, Xuehua Hou, Yinfang Wu, Qiang Cui, Na Yan, Ruobing Ma, Lingjian Wang, Ming Yao, Kai Wang
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-5 (2018)
Abstract Background Cholangiocarcinoma, or bile duct cancer, is a gastrointestinal cancer with limited therapeutic options and a poor outcome. Studies have revealed that some major driver genes are associated with cholangiocarcinoma, but no targeted
Externí odkaz:
https://doaj.org/article/4e4d89fbace84cccbfe13ec68a73ad8a
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Objective: The specific purpose of this study is to investigate the impact exosomes from adipose-derived mesenchymal stem cell (AMSC) has on non-small cell lung carcinoma (NSCLC) and the relative applications. Methods: circ_100395, miR-141-3p, and LA
Externí odkaz:
https://doaj.org/article/bdde9991b75649ee93f25f01ea99b67a
Autor:
Jingjing Li, Qing Wei, Xiaoying Wu, Jun Sima, Qi Xu, Mengmeng Wu, Fufeng Wang, Haibo Mou, Hanguang Hu, Jianguo Zhao, Da Li, Jinlin Hu, Lingnan Zhang, Xiu Zhu, Lei Chen, Cong Luo, Junrong Yan, Jiachen He, Yutong Ma, Yang Shao, Wei Wu, Jieer Ying
Publikováno v:
Clinical and Translational Medicine, Vol 10, Iss 4, Pp n/a-n/a (2020)
Abstract Background While there have been encouraging preliminary clinical results for immune checkpoint inhibitors (ICIs) in BTCs, it remains a challenge to identify the subset of patients who may benefit. In this study, we evaluated the efficacy of
Externí odkaz:
https://doaj.org/article/fc39024e233146edaa645bd4069ce501
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58891 (2013)
BACKGROUND: Cyclooxygenase-2 (COX-2) is believed to be an important enzyme in the pathogenesis of colorectal cancer (CRC). Correlations between the expression of COX-2 with tumor growth and distant metastasis have become an issue; thus, attention has
Externí odkaz:
https://doaj.org/article/608a6152dd794283ae4f4b9b567a1590
Publikováno v:
Kidney Dis (Basel)
Kidney Diseases, Pp 1-18 (2021)
Kidney Diseases, Pp 1-18 (2021)
Background: Cells of the immune system can inhibit tumor growth and progression; however, immune cells can also promote tumor cell growth, survival, and angiogenesis as a result of the immunosuppressive microenvironments. In the last decade, a growin
Autor:
Thomas Yau, Lili Qian, Rong Shen, Lanfang Yu, Yi Dai, Donglin Chen, Shuang Wang, Qing Wan, Ting Wang, Xuemei Wang, Kui Liu, Qiu‐an Yang, Fangling Zhou, Xuedong Pan, Xiaowei Dong, Haibo Mou
Publikováno v:
Journal of Gastroenterology and Hepatology
Background and Aim Programmed cell death‐ligand 1 (PD‐L1) immunohistochemistry score has been approved as the predictive biomarker for anti‐PD1/PD‐L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive